CBAY
Cymabay Therapeutics
CBAY
CBAY
Delisted
CBAY was delisted on the 21st of March, 2024.
120 hedge funds and large institutions have $416M invested in Cymabay Therapeutics in 2020 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 29 increasing their positions, 42 reducing their positions, and 23 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
120
Holders Change
+6
Holders Change %
+5.26%
% of All Funds
2.43%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.06%
New
29
Increased
29
Reduced
42
Closed
23
Calls
$3.5M
Puts
$951K
Net Calls
+$2.54M
Net Calls Change
+$2.16M
Top Buyers
| 1 |
ACA
Avoro Capital Advisors
New York
|
$74.6M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
$29M |
| 3 |
Invesco
Atlanta,
Georgia
|
$13.6M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
$23.5M |
| 5 |
VOYA Investment Management
Atlanta,
Georgia
|
$6.12M |
Top Sellers
| 1 |
D.E. Shaw & Co
New York
|
$12.2M |
| 2 |
SCM
Sio Capital Management
New York
|
$8.39M |
| 3 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
$12.9M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
$10.5M |
| 5 |
Citigroup
New York
|
$119K |
